A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
Sir John Vickers proposed reforms to make the financial system safer. Now he has accused the Bank of England of "going easy" on the banks.
Widespread frost expected overnight as temperatures drop below freezing ahead of a chilly start to the week.
Obese people make a mountain out a molehill - because they see distances as further and hills as steeper than slim people, say scientists.